Biodeal Pharma Expands Injectable Manufacturing with Biological E Facility Acquisition

Biodeal Pharmaceuticals Limited has significantly strengthened its sterile injectable manufacturing and contract development and manufacturing organization (CDMO) capabilities by acquiring a manufacturing facility owned by Biological E. Limited located in Paonta Sahib, Himachal Pradesh.

Strategic Expansion and Facility Details

Scale and Capacity: The acquired manufacturing plant spans approximately 14 acres and boasts an annual production capacity of roughly 135 million units.
Current Capabilities: The site currently supports the production of general injectable products and carbapenems in vial formats.
Future Upgrades: Biodeal plans to expand the facility’s capabilities to encompass advanced injectable formats, including lyophilised injectable products and pre-filled syringes (PFS).

Investment and Regulatory Goals

Financial Outlay: The acquisition and planned investments total more than ₹400 crore, aimed at scaling infrastructure and enhancing regulatory standards.
Global Compliance: Biodeal is actively pursuing European Union and PIC/S accreditations for the site to facilitate expansion into regulated international markets.
CDMO Integration: The Paonta Sahib plant complements Biodeal’s existing portfolio, which spans pharmaceutical formulations, nasal drug delivery, dry powder inhalers, capsules, tablets, and nutraceutical products.

This strategic move marks a major milestone in Biodeal Pharmaceuticals’ vision to build a robust, globally competitive, and integrated pharmaceutical CDMO platform originating from India.